Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.67 |
| ▸ | AGTR1 | P30556 | 6/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8569736 | 0.86 | GP6 (0.69) | GP6AGTR1AGTR2 | |
| SCHEMBL1457880 | 0.84 | GP6 (0.65) | GP6AGTR1AGTR2 | |
| SCHEMBL1459519 | 0.84 | GP6 (0.65) | GP6AGTR1AGTR2 | |
| SCHEMBL24360483 | 0.84 | AGTR1 (0.70) | AGTR1AGTR2 | |
| SCHEMBL1014 | 0.83 | GP6 (0.66) | GP6AGTR1AGTR2 | |
| SCHEMBL33 | 0.83 | AGTR1 (0.75) | GP6AGTR1AGTR2 | |
| SCHEMBL2276369 | 0.83 | GP6 (0.61) | GP6AGTR1AGTR2 | |
| SCHEMBL965839 | 0.83 | AGTR1 (0.67) | GP6AGTR1AGTR2 | |
| SCHEMBL1258200 | 0.82 | GP6 (0.60) | GP6AGTR1AGTR2 | |
| SCHEMBL359 | 0.81 | GP6 (0.63) | GP6AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | HETERO LABS LIMITED (IN) | 2023-05-23 | — | — | US | disclosed |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | HETERO LABS LIMITED (IN) | 2023-05-23 | — | — | US | disclosed |
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | HETERO LABS LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | AGTR2, AGTR1, ADRB1 | GP6 1372/4885AGTR1 2/4885AGTR2 1/4885 |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | AGTR2, AGTR1, ADRB1 | GP6 1372/4885AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.